Research summary

Psilocybin for cluster headaches: what the research shows.

A plain-language summary of what patient surveys and early trials have observed about psilocybin and cluster headache. This is education, not medical advice. Talk to your neurologist before changing any treatment. If you are in crisis, call or text 988.

A warmly lit bedroom with a wooden bed, an armchair and French doors

In brief

  • The main clinical studies. Three patient-reported studies (Sewell 2006, 53 interviewed; Schindler 2015, 496 cluster headache patients surveyed; Andersson 2017, a qualitative study of forum posts), one small randomized trial in cluster headache (Schindler 2022, 14 analysed), and one small randomized trial in migraine (Schindler 2021, 10 analysed). The table below lists all eight studies.
  • What the cluster headache trial found. The primary result was not statistically significant: change in attacks per week of -3.2 with psilocybin and +0.03 with placebo (p=0.251).
  • What that means. The evidence is early and mostly patient-reported. Psilocybin is investigational for cluster headache, and it is not approved by the FDA for it.
  • What to do with it. Read it with your neurologist. Do not start, stop or change any treatment, or add anything to your current medication, on the strength of a summary like this one.

Background: cluster headache, “the suicide headache”

Cluster headache affects roughly 0.1 percent of the population over a lifetime, with episodic and chronic patterns. Attacks are routinely rated 10/10 on pain scales, hence the colloquial name. Standard care includes oxygen therapy and triptans for acute attacks, with verapamil, CGRP-modulating monoclonals, and occipital nerve blocks for prevention. Many patients remain incompletely controlled.

The patient-led Clusterbusters community organized self-reported data on psilocybin and LSD use for cluster headaches in the early 2000s. Halpern and Sewell (2005, Life Sciences) framed that patient-led use as a research priority, a year before the first published case series (Sewell 2006, Neurology). The surveys cited below followed and, eventually, the Yale RCT program led by Schindler and colleagues.

Mechanism: hypothesized circuit involvement

Cluster headache neurobiology features trigeminovascular activation and hypothalamic involvement, demonstrated by PET imaging studies (Goadsby 2002 and successors). The serotonergic targets exploited by triptans (5-HT1B/1D agonists) have led researchers to ask whether psilocybin, through overlapping receptor pharmacology and its 5-HT2A action, could be a candidate. That is a hypothesis. The studies below do not show that it explains any effect.

The Karst et al. (2010) BOL-148 case series, using a non-hallucinogenic LSD analog, was a small open-label, non-randomized series. It is suggestive that the cluster-abortive effect may be pharmacological rather than experience-driven, but it is not proof of mechanism. Pulse protocols are studied separately from the single-session protocols used in depression and anxiety trials.

A single flower resting on a white sheet
A single flower on a white sheet.

Clinical evidence: small and preliminary

The table lists all eight studies. They answer different questions, so it helps to read them in four groups.

  • Patient reports (Sewell 2006; Schindler 2015; Andersson 2017). These describe what people who chose psilocybin, LSD or other psychoactive substances said afterward. The samples are self-selected and retrospective, so they cannot separate the drug from other explanations. Cluster headache has episodic patterns, so a good stretch after a dose may or may not be linked to the dose.
  • Controlled trials (Schindler 2021 in migraine; Schindler 2022 in cluster headache). These used a placebo, which patient reports do not, but both are small and exploratory. The 2021 migraine trial is included as adjacent headache evidence, not as cluster headache evidence.
  • Mechanism and a related compound (Goadsby 2002; Karst 2010). These explain why researchers look at serotonergic targets and report a small open-label series of a non-hallucinogenic LSD analog. Neither tests psilocybin in cluster headache.
  • Background (Halpern and Sewell 2005). A review that framed the research need.

Honest caveat

Cluster-headache evidence is dominated by patient-reported survey data and one small randomized trial. The mechanism is plausible. The trial scale is small. What follows is an honest summary of the published literature; high-quality phase III data do not yet exist.

Cited studies: design, sample size, primary outcome and reported effect
StudyDesign and samplePrimary outcomeReported effect
Response of cluster headache to psilocybin and LSDSewell RA, Halpern JH, Pope HG.
Neurology · 2006
DOI: 10.1212/01.wnl.0000219761.05466.43
Retrospective interview-based case series53 (cluster headache patients self-reporting psilocybin or LSD use)Self-reported cycle abortion, attack frequency, and remission extensionOf 53 interviewed patients, 22 of 26 psilocybin users (85%) said it aborted individual attacks, 25 of 48 (52%) reported cluster-period termination, and 18 of 19 (95%) reported remission-period extension. Retrospective, self-selected interviews; the first published case series of the patient-led use.
Indoleamine hallucinogens in cluster headache: results of the Clusterbusters Medication Use SurveySchindler EAD, Gottschalk CH, Weil MJ, et al.
Journal of Psychoactive Drugs · 2015
DOI: 10.1080/02791072.2015.1107664
Retrospective survey (Clusterbusters cohort)496 (cluster headache patients)Self-reported comparative efficacy of psilocybin and LSD vs standard cluster headache abortive and preventive therapiesSurvey respondents rated psilocybin and LSD as effective in cluster headache; the authors called for controlled studies. A retrospective survey of a patient-advocacy cohort.
Exploratory controlled study of the migraine-suppressing effects of psilocybinSchindler EAD, Sewell RA, Gottschalk CH, et al.
Neurotherapeutics · 2021
DOI: 10.1007/s13311-020-00962-y
Randomized, double-blind, placebo-controlled exploratory trial10 (migraine, included as adjacent headache evidence)Weekly migraine days post-administrationA single psychoactive dose (0.143 mg/kg, roughly 10 mg for a 70 kg adult) was followed by a reduction of 1.65 weekly migraine days (95% CI 0.77 to 2.53) after psilocybin vs 0.15 after placebo (p=0.003); crossover, n=10 analysed, exploratory (Schindler et al., 2021).
Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trialSchindler EAD, Sewell RA, Gottschalk CH, et al.
Headache · 2022
DOI: 10.1111/head.14420
Randomized, double-blind, placebo-controlled (Yale)14 analysed (cluster headache patients)Change in cluster attacks per weekThree doses of 0.143 mg/kg, five days apart. The primary result was not statistically significant: change in attacks per week -3.2 with psilocybin vs +0.03 with placebo (p=0.251). A 2024 blinded extension without a concurrent placebo comparator (n=10) reported attacks falling from 18.4 to 9.8 per week (Schindler et al., J Neurol Sci 2024). Small N, exploratory.
The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headacheKarst M, Halpern JH, Bernateck M, Passie T.
Cephalalgia · 2010
DOI: 10.1177/0333102410363490
Open, non-randomized case seriesSmall case series (BOL-148)Cluster cycle abortion and remissionA small open-label, non-randomized case series of a non-hallucinogenic LSD analog; suggestive of a pathway independent of the psychedelic experience, but not proof of mechanism.
Pathophysiology of cluster headache: a trigeminal autonomic cephalgiaGoadsby PJ.
Lancet Neurology · 2002
DOI: 10.1016/S1474-4422(02)00104-7
Mechanism reviewReviewTrigeminovascular activation and hypothalamic involvement in cluster headacheEstablished the trigeminal-autonomic cephalgia framework and hypothalamic involvement (PET imaging), the framework researchers cite when discussing serotonergic targets.
Hallucinogenic botanicals of America: a growing need for focused drug education and researchHalpern JH, Sewell RA.
Life Sciences · 2005
DOI: 10.1016/j.lfs.2005.04.012
ReviewReviewPublic-health framing of hallucinogen pharmacology and clinical research needFramed the patient-led use of hallucinogens for cluster headache as a research priority, preceded the 2006 Sewell case series.
Psychoactive substances as a last resort: a qualitative study of self-treatment of migraine and cluster headachesAndersson M, Persson M, Kjellgren A.
Harm Reduction Journal · 2017
DOI: 10.1186/s12954-017-0186-6
Qualitative analysis of online forum postsSelf-selected migraine and cluster headache postsPerceived effectiveness of self-treatment with psychoactive substancesReports perceived effectiveness among self-selected forum users; not a replicated efficacy signal.

What an exploratory headache study can answer

An exploratory randomized, placebo-controlled study investigated a low-dose psilocybin pulse regimen for cluster headache. Its purpose was to examine an early research question in a small group, not to establish a standard treatment. Headache patterns can vary between people and over time, which makes comparison and follow-up particularly important.

A person with cluster headache needs an individualized plan with a qualified clinician, including what to do during attacks and how to use established treatments. A study regimen is not a dosing guide for home use. Read the paper alongside its limitations and bring questions about ongoing symptoms or medications to your care team.

Safety profile specific to cluster headaches

Your prescriber leads any change to your headache regimen. Never stop or change a medication on your own.

  • Triptans: risk of serotonin syndrome if combined acutely with psilocybin; wash-out is required and must be supervised. See Medications.
  • Verapamil: talk to your prescriber before anything changes. Cardiovascular monitoring during a session is appropriate.
  • Lithium and valproate (sometimes used in chronic cluster headache): lithium does not mix with this work, as the Medications guide explains. With valproate, caution; your prescriber leads any change.
  • Cardiovascular pre-existing conditions: psilocybin produces transient blood pressure and heart rate elevation, relative contraindication in unstable cardiac disease. See Screening.
  • Chronic vs. episodic cluster headache: the published trials and surveys distinguish these phenotypes; chronic cluster headache is a higher-bar use case for any investigational care.

Tracking and follow-up for cluster headaches

Cluster headache is primarily a neurological condition. After any treatment, the useful work looks less like psycho-spiritual reflection and more like pattern tracking: a daily headache diary, an attack frequency log, careful notes on triggers and remissions. The useful end-state is data the patient can bring back to a neurologist.

Low mood and anxiety can accompany chronic severe pain, and the framings used in the depression and anxietyresearch summaries may overlap. The Clusterbusters community uses the term “busting protocol”, a pharmacological framing, not a psychedelic-experience framing.

Questions to bring to your neurologist

If this summary raised questions, these are the ones the studies and safety notes above point to.

  1. Is my cluster headache episodic or chronic? The studies and surveys distinguish the two.
  2. Which of my current acute and preventive medications matter here, including any triptan, verapamil, lithium or valproate? Who leads any change?
  3. How are my heart and blood pressure? Psilocybin produces transient blood pressure and heart rate elevation.
  4. Are there active trials I could ask about? ClinicalTrials.gov is the primary registry; search for psilocybin or LSD studies in headache or cluster headache.
  5. What should I be tracking, and what would you want to see? A diary of attacks, triggers and remissions is a start.

Practitioner perspective

“Cluster headache work is a different conversation. It is primarily a neurological condition. Our job at intake is to ask whether a Ceremonia program is the right pathway at all, or whether a referral into the Yale-led trial network or a cluster-headache-specialist neurologist is the better next step.”
Austin Mao

Thinking about your own situation?

  1. Read our safety overview and medication guidance. Many cluster headache medications require tapering or are absolute exclusions.
  2. If you are medically cleared, start with our intake conversation (free, about 30 minutes, with someone on our team). We will tell you honestly if Ceremonia is the right fit, or refer you elsewhere.

Note on scope: Cluster headache care often falls outside our typical 1:1 retreat scope. We may refer you to a neurology-led clinical trial (for example, the Yale-led psilocybin pulse research described above) or to a headache-specialist neurologist familiar with the published evidence. The intake conversation for the Heal journey is where that is decided.

We do not accept self-bookings for clinical conditions.

FAQ

Common questions about psilocybin for cluster headaches

  • Why have researchers studied psilocybin for cluster headaches?
    Two reasons. First, psilocybin shares some receptor activity (5-HT1B and 5-HT1D) with the triptan family, which researchers have proposed as a possible pathway for aborting a cycle, independent of any psychedelic effect. That is a hypothesis, not an established mechanism. Second, the Clusterbusters patient community documented self-reported response patterns over years before academic interest formed. That grassroots signal motivated the Sewell case series and the Yale randomized trial under Schindler.
  • What is the dosing protocol? Is it sub-perceptual?
    The Yale cluster-headache trial used a pulse regimen of three doses of 0.143 mg/kg (about 10 mg for a 70 kg adult) separated by five days. The authors called it a patient-informed low-dose regimen, but participants had acute psychotropic effects, and attack changes did not correlate with their intensity. Depression and anxiety protocols typically use one or two sessions paired with psychological support. This describes a study protocol, not a dosing guide.
  • Is this the same protocol as for depression or anxiety?
    No. Cluster-headache protocols use lower doses, a pulse schedule rather than a single session, and lighter psychological support. A Ceremonia retreat is a ceremonial program with preparation and integration, not a clinical protocol for any condition. Cluster-headache work usually belongs in a neurology setting or a dedicated clinical trial, not a retreat.
  • Can I do this while taking a triptan?
    Acute combination of triptans with psilocybin carries serotonin syndrome risk and requires a wash-out. Lithium does not mix with this work, and verapamil is one to raise with your prescriber, with cardiovascular monitoring during a session. Your prescriber leads any change to your headache regimen; never change a medication on your own. Read the medications guide
  • How do I find a neurology trial?
    ClinicalTrials.gov is the primary registry. Search for active psilocybin or LSD studies in headache or cluster headache. The 2022 randomized trial in the table above was run at Yale under Dr. Emmanuelle Schindler. Cluster headache care at Ceremonia is outside our typical scope. The care path section above explains how we handle it, which may include a referral to a neurology trial.
  • Is this approved by the FDA for cluster headaches?
    No. As of 2026 psilocybin is investigational for cluster headaches. The evidence base is dominated by retrospective patient-survey data (Sewell 2006, Schindler 2015) plus a small Yale randomized trial (Schindler 2022, n=14) whose primary result was not statistically significant. Mechanism is plausible; trial scale is small.
  • Should I try this on my own?
    We do not advise it. A study regimen is not a dosing guide for home use, and attacks, medications and heart health all matter. Psilocybin remains a Schedule I substance under U.S. federal law. The people who know your case are your neurologist and your care team. For a medical question about your own situation, email info@ceremoniacircle.org. If you are in crisis, call or text 988.

Start with the people who know your case.

Cluster headache care often falls outside our typical retreat scope, and your neurologist leads yours. If you still have questions for us, the intake conversation for the Heal journey is where we tell you honestly whether Ceremonia is the right fit, or refer you elsewhere.